![Lisa Stockman Mauriello w/ fam](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2021/03/IMG_0228-645x645.jpeg)
It’s been two weeks since Lisa Stockman Mauriello passed away and a lingering question, in my mind, is whether she died in vain.
I’d like to think not.
During her final months, the 52-year-old former public relations executive battled Biogen, one of the world’s largest biotech companies, for access to an experimental treatment for ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis.
![STAT+](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2022/02/stat_plus_hero_new-2048x502.png)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect